Skip to main content

Table 3 Summary of second outcomes in this meta-analysis

From: Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis

Outcome of interest RPC + BRPC RPC BRPC
Data sets ES (95% CIs) P value I2 (%) Data sets ES (95% CIs) P value I2 (%) Data sets ES (95% CIs) P value I2 (%)
DFS 7 0.66 (0.53–0.83) < 0.001 0 3 0.80 (0.59–1.07) 0.137 0 2 0.44 (0.26–0.73) 0.002 0
Overall resection rate 12 0.64 (0.37–1.10) 0.104 60.0 6 0.50 (0.25–0.99) 0.048 60.4 5 0.69 (0.41–1.16) 0.159 36.1
R0 rate 19 2.83 (2.19–3.65) < 0.001 40.2 8 1.95 (1.40–2.71) < 0.001 22.3 6 4.75 (2.85–7.92) < 0.001 16.4
Recurrence 12 0.65 (0.50–0.86) 0.003 0 4 0.77 (0.55–1.08) 0.131 0 5 0.41 (0.22–0.76) 0.005 10.2
pN+ rate 18 0.30 (0.20–0.43) < 0.001 58.4 7 0.28 (0.21–0.38) < 0.001 0 6 0.23 (0.07–0.75) 0.015 82.8
  1. DFS disease-free survival, pN+ pathological positive lymph node, ES indicates effect size